questionsmedicales.fr
Actions chimiques et utilisations
Utilisations spécialisées de produits chimiques
Agents séquestrants
Agents séquestrants : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Intoxication aux métaux
Tests de laboratoire
Évaluation de traitement
Biochimie clinique
Symptômes digestifs
Troubles gastro-intestinaux
Carence nutritionnelle
Tests sanguins
Overdose
Effets indésirables
Symptômes
5
Toxicité au plomb
Symptômes neurologiques
Carence en calcium
Symptômes musculaires
Intoxication au mercure
Symptômes neurologiques
Carence en potassium
Symptômes cardiaques
Prévention
5
Prévention des carences
Nutrition
Exposition aux métaux
Prévention
Cholestérol
Régime alimentaire
Effets indésirables
Conseils médicaux
Traitements
5
Mécanisme d'action
Absorption intestinale
Effets indésirables
Troubles gastro-intestinaux
Administration orale
Formes pharmaceutiques
Intoxication aux métaux
EDTA
Complications
5
Surconsommation
Complications
Utilisation prolongée
Déséquilibres électrolytiques
Interactions médicamenteuses
Absorption
Intoxication au plomb
Complications
Effets à long terme
Troubles métaboliques
Facteurs de risque
5
Facteurs de risque
Carences nutritionnelles
Intoxication au mercure
Risque alimentaire
Carence en calcium
Groupes vulnérables
Intoxication aux métaux
Comportements à risque
Absorption des nutriments
Facteurs influents
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Agents séquestrants : Questions médicales les plus fréquentes",
"headline": "Agents séquestrants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Agents séquestrants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-03",
"dateModified": "2025-04-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Agents séquestrants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Utilisations spécialisées de produits chimiques",
"url": "https://questionsmedicales.fr/mesh/D020313",
"about": {
"@type": "MedicalCondition",
"name": "Utilisations spécialisées de produits chimiques",
"code": {
"@type": "MedicalCode",
"code": "D020313",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Chélateurs",
"alternateName": "Chelating Agents",
"url": "https://questionsmedicales.fr/mesh/D002614",
"about": {
"@type": "MedicalCondition",
"name": "Chélateurs",
"code": {
"@type": "MedicalCode",
"code": "D002614",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agents chélateurs du calcium",
"alternateName": "Calcium Chelating Agents",
"url": "https://questionsmedicales.fr/mesh/D065096",
"about": {
"@type": "MedicalCondition",
"name": "Agents chélateurs du calcium",
"code": {
"@type": "MedicalCode",
"code": "D065096",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.204"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Agents chélateurs du fer",
"alternateName": "Iron Chelating Agents",
"url": "https://questionsmedicales.fr/mesh/D007502",
"about": {
"@type": "MedicalCondition",
"name": "Agents chélateurs du fer",
"code": {
"@type": "MedicalCode",
"code": "D007502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.410"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Sidérophores",
"alternateName": "Siderophores",
"url": "https://questionsmedicales.fr/mesh/D017262",
"about": {
"@type": "MedicalCondition",
"name": "Sidérophores",
"code": {
"@type": "MedicalCode",
"code": "D017262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.410.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Sidérophores",
"alternateName": "Siderophores",
"url": "https://questionsmedicales.fr/mesh/D017262",
"about": {
"@type": "MedicalCondition",
"name": "Sidérophores",
"code": {
"@type": "MedicalCode",
"code": "D017262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.410.750"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Agents séquestrants",
"alternateName": "Sequestering Agents",
"code": {
"@type": "MedicalCode",
"code": "D064449",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xueli Cao",
"url": "https://questionsmedicales.fr/author/Xueli%20Cao",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China."
}
},
{
"@type": "Person",
"name": "Yu Xiao",
"url": "https://questionsmedicales.fr/author/Yu%20Xiao",
"affiliation": {
"@type": "Organization",
"name": "Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Tsinghua-Peking Center for Life Sciences, Beijing 100084, China."
}
},
{
"@type": "Person",
"name": "Erin Huiting",
"url": "https://questionsmedicales.fr/author/Erin%20Huiting",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA."
}
},
{
"@type": "Person",
"name": "Dong Li",
"url": "https://questionsmedicales.fr/author/Dong%20Li",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China."
}
},
{
"@type": "Person",
"name": "Jie Ren",
"url": "https://questionsmedicales.fr/author/Jie%20Ren",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory for Biology of Plant Diseases and Insect Pests, Ministry of Agriculture, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing 100081, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cyclin D1 expression in penile cancer.",
"datePublished": "2024-05-14",
"url": "https://questionsmedicales.fr/article/38742684",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/oncotarget.28584"
}
},
{
"@type": "ScholarlyArticle",
"name": "A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction.",
"datePublished": "2023-02-19",
"url": "https://questionsmedicales.fr/article/36808524",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10549-023-06866-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cyclin D1 promotes radioresistance through regulation of RAD51 in melanoma.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37421206",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/exd.14877"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Potential of Expression of Cyclin-D1 on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma.",
"datePublished": "2023-04-01",
"url": "https://questionsmedicales.fr/article/37116133",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31557/APJCP.2023.24.4.1131"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multiple cullin-associated E3 ligases regulate cyclin D1 protein stability.",
"datePublished": "2023-11-09",
"url": "https://questionsmedicales.fr/article/37943017",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7554/eLife.80327"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Utilisations spécialisées de produits chimiques",
"item": "https://questionsmedicales.fr/mesh/D020313"
},
{
"@type": "ListItem",
"position": 4,
"name": "Agents séquestrants",
"item": "https://questionsmedicales.fr/mesh/D064449"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Agents séquestrants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Agents séquestrants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Agents séquestrants",
"description": "Comment diagnostiquer une intoxication aux métaux lourds ?\nQuels examens pour évaluer l'efficacité d'un agent séquestrant ?\nQuels symptômes indiquent un besoin d'agents séquestrants ?\nComment identifier une carence nutritionnelle ?\nQuels signes d'overdose d'agents séquestrants ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cyclin+D1#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Agents séquestrants",
"description": "Quels symptômes d'une carence en fer ?\nComment reconnaître une toxicité au plomb ?\nQuels signes d'une carence en calcium ?\nQuels symptômes d'une intoxication au mercure ?\nComment se manifeste une carence en potassium ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cyclin+D1#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Agents séquestrants",
"description": "Comment prévenir les carences nutritionnelles ?\nQuelles mesures pour éviter l'exposition aux métaux lourds ?\nComment réduire le cholestérol par l'alimentation ?\nQuels aliments riches en calcium pour la prévention ?\nComment éviter les effets secondaires des séquestrants ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cyclin+D1#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Agents séquestrants",
"description": "Quels agents séquestrants pour le cholestérol ?\nComment fonctionnent les agents séquestrants ?\nQuels sont les effets secondaires des agents séquestrants ?\nComment administrer un agent séquestrant ?\nQuels agents séquestrants pour les métaux lourds ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cyclin+D1#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Agents séquestrants",
"description": "Quelles complications d'une surconsommation d'agents séquestrants ?\nQuels risques d'une utilisation prolongée ?\nComment les agents séquestrants affectent-ils l'absorption des médicaments ?\nQuelles complications liées à l'intoxication au plomb ?\nQuels effets à long terme des agents séquestrants ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cyclin+D1#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Agents séquestrants",
"description": "Quels facteurs augmentent le risque de carences ?\nQui est à risque d'intoxication au mercure ?\nQuels groupes sont vulnérables aux carences en calcium ?\nQuels comportements augmentent le risque d'intoxication aux métaux ?\nQuels facteurs influencent l'absorption des nutriments ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Cyclin+D1#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux métaux lourds ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et urinaires peuvent détecter la présence de métaux lourds."
}
},
{
"@type": "Question",
"name": "Quels examens pour évaluer l'efficacité d'un agent séquestrant ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses biochimiques peuvent mesurer les niveaux de nutriments ou toxines."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'agents séquestrants ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs abdominales ou des troubles digestifs peuvent indiquer un besoin."
}
},
{
"@type": "Question",
"name": "Comment identifier une carence nutritionnelle ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins peuvent révéler des carences en vitamines ou minéraux."
}
},
{
"@type": "Question",
"name": "Quels signes d'overdose d'agents séquestrants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées, vomissements ou diarrhées peuvent signaler une overdose."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une carence en fer ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, pâleur, essoufflement et vertiges sont des symptômes courants."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une toxicité au plomb ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales, des troubles neurologiques et des anémies peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels signes d'une carence en calcium ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crampes musculaires, des engourdissements et des troubles de l'humeur peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une intoxication au mercure ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tremblements, des troubles de la mémoire et des problèmes de vision peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une carence en potassium ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des faiblesses musculaires, des palpitations et des troubles du rythme cardiaque peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir les carences nutritionnelles ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et variée est essentielle pour éviter les carences."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour éviter l'exposition aux métaux lourds ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments contaminés et utiliser des filtres à eau peut réduire l'exposition."
}
},
{
"@type": "Question",
"name": "Comment réduire le cholestérol par l'alimentation ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consommer des fibres solubles et limiter les graisses saturées aide à réduire le cholestérol."
}
},
{
"@type": "Question",
"name": "Quels aliments riches en calcium pour la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les produits laitiers, les légumes verts et les noix sont de bonnes sources de calcium."
}
},
{
"@type": "Question",
"name": "Comment éviter les effets secondaires des séquestrants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Prendre les agents séquestrants avec suffisamment d'eau et suivre les recommandations médicales."
}
},
{
"@type": "Question",
"name": "Quels agents séquestrants pour le cholestérol ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résines comme le cholestyramine sont utilisées pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les agents séquestrants ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils se lient aux substances dans l'intestin, empêchant leur absorption dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des agents séquestrants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets comme des ballonnements, des nausées et des troubles digestifs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment administrer un agent séquestrant ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement pris par voie orale, souvent mélangés à des liquides."
}
},
{
"@type": "Question",
"name": "Quels agents séquestrants pour les métaux lourds ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents comme l'EDTA sont utilisés pour traiter les intoxications aux métaux lourds."
}
},
{
"@type": "Question",
"name": "Quelles complications d'une surconsommation d'agents séquestrants ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surconsommation peut entraîner des carences nutritionnelles et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Quels risques d'une utilisation prolongée ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une utilisation prolongée peut causer des déséquilibres électrolytiques et des carences."
}
},
{
"@type": "Question",
"name": "Comment les agents séquestrants affectent-ils l'absorption des médicaments ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'absorption de certains médicaments, diminuant leur efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications liées à l'intoxication au plomb ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques, rénales et cardiovasculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels effets à long terme des agents séquestrants ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets à long terme peuvent inclure des carences nutritionnelles et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de carences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée, des maladies chroniques et des régimes restrictifs augmentent le risque."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'intoxication au mercure ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes consommant régulièrement des poissons contaminés sont à risque élevé."
}
},
{
"@type": "Question",
"name": "Quels groupes sont vulnérables aux carences en calcium ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées, les femmes enceintes et les végétariens peuvent être plus vulnérables."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent le risque d'intoxication aux métaux ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Travailler dans des environnements contaminés ou utiliser des produits non réglementés augmente le risque."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent l'absorption des nutriments ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, la santé digestive et les interactions médicamenteuses influencent l'absorption."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 28/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Publications dans "Agents séquestrants" :
3 publications dans cette catégorie
Affiliations :
Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Tsinghua-Peking Center for Life Sciences, Beijing 100084, China.
Publications dans "Agents séquestrants" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Publications dans "Agents séquestrants" :
3 publications dans cette catégorie
Affiliations :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Publications dans "Agents séquestrants" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory for Biology of Plant Diseases and Insect Pests, Ministry of Agriculture, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
Publications dans "Agents séquestrants" :
3 publications dans cette catégorie
Affiliations :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Publications dans "Agents séquestrants" :
3 publications dans cette catégorie
Affiliations :
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; Innovative Genomics Institute, Berkeley, CA 94720, USA. Electronic address: joseph.bondy-denomy@ucsf.edu.
Publications dans "Agents séquestrants" :
3 publications dans cette catégorie
Affiliations :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. Electronic address: fengyue@mail.buct.edu.cn.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Department of Animal Science and Technology, Konkuk University, Seoul 05029, Korea.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Molecular Neuroscience, German Center for Neurodegenerative Diseases (DZNE), 10117, Berlin, Germany.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Molecular Neuroscience, German Center for Neurodegenerative Diseases (DZNE), 10117, Berlin, Germany.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Molecular Neuroscience, German Center for Neurodegenerative Diseases (DZNE), 10117, Berlin, Germany. dragomir.milovanovic@dzne.de.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, School of Science, The University of Tokyo, Tokyo, Japan. ozawa@chem.s.u-tokyo.ac.jp.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
ABLife BioBigData Institute, Wuhan, Hubei, China. yizhang@ablife.cc.
Center for Genome Analysis, ABLife Inc., Wuhan, Hubei, China. yizhang@ablife.cc.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Stanford University, Stanford, CA 94305, USA; Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; Sarafan ChEM-H Institute, Stanford University, Stanford, CA 94305, USA; Arc Institute, Palo Alto, CA 94304, USA.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Publications dans "Agents séquestrants" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; Sarafan ChEM-H Institute, Stanford University, Stanford, CA 94305, USA; Arc Institute, Palo Alto, CA 94304, USA.
Publications dans "Agents séquestrants" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Fudan University Shanghai 200438 China zhouw@fudan.edu.cn zhangdw@fudan.edu.cn ztli@fudan.edu.cn.
Publications dans "Agents séquestrants" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Fudan University Shanghai 200438 China zhouw@fudan.edu.cn zhangdw@fudan.edu.cn ztli@fudan.edu.cn.
Publications dans "Agents séquestrants" :
The main goal of the present study was to analyze the expression profile of cyclin D1 in patients with PC, and to determine possible correlations with clinical and histopathological features. A survey...
Cyclin D1 overexpression may contribute to development of various cancers, including breast cancer, and thus may serve as a key cancer diagnostic marker and therapeutic target. In our previous study, ...
Here, using phage display and in silico protein structure modeling methods combined with cyclin D1 mutational analysis, key residues that bind to ADκ were identified. Notably, residue K112 within the ...
We identified amino acid residues in cyclin D1 that may play key roles in the ADκ-cyclin D1 interaction. A nuclear localization antibody against cyclin D1 (NLS-ADκ) was constructed and successfully ex...
Melanoma is a notoriously radioresistant type of skin cancer. Elucidation of the specific mechanisms underlying radioresistance is necessary to improve the clinical efficacy of radiation therapy. To i...
Patients undergoing neoadjuvant chemotherapy (NC) for invasive breast cancer (IBC) need indicators to track their progress during treatment. The goal of this research is to learn how cyclin D1 works i...
There were 31 examples divided into two groups, based on: those using a different type of NC (taxane- or non-taxane-based), and NC administration time (before or after). Tumor grade, age, PR, ER, Ki-6...
The expression of Cyclin D1 decreased after NC delivery (p=0.086). Cyclin D1 expression was reduced in the taxane group (p=0.792). The non-taxane group also saw no differences in outcomes (p = 0.065)....
Cyclin D1 expression, even if the differences are not statistically significant, may be a prognostic indicator of NC reaction in IBC. The involvement of Cyclin D1 in NC warrants more research with big...
Cyclin D1 is a key regulator of cell cycle progression, which forms a complex with CDK4/6 to regulate G1/S transition during cell cycle progression. Cyclin D1 has been recognized as an oncogene since ...
Cyclin D1 (CCND1), a crucial mediator of cell cycle progression, possesses many mutation types with different mutation frequencies in human cancers. The G870A mutation is the most common mutation in C...
With the continuous discovery of new borderline thyroid lesions and benign and malignant "gray areas", coupled with the limitations of traditional immune indicators, the differential diagnosis of papi...
In our study, immunohistochemical staining was used to explore the expression of Cyclin D1 and P21 in PTC, paracancerous tissue, follicular adenoma (FA) and papillary thyroid hyperplasia. In addition,...
Among 200 primary PTC lesions, Cyclin D1 and P21 were found to be expressed in 186 (93.00%) and 177 (88.50%), respectively, and their expression levels were significantly higher in PTC tissue than in ...
The results of our study show that Cyclin D1 and P21 are highly sensitive and specific markers for the diagnosis of PTC that are superior to traditional classical antibodies. And, these two markers ar...
Mantle cell lymphoma (MCL) is a rare B-cell malignancy with a predominantly aggressive clinical course and poor prognosis. Abnormal expression of Ambra1 is closely related to the occurrence and develo...
One of the biggest therapy challenges for nasopharyngeal cancer (NPC) is still radioresistance. The radioresistance in NPC is thought to be caused by cyclin D1 overexpression. The purpose of this stud...
Adhering to the PRISMA guidelines, we systematically reviewed studies on cyclin D1-associated radioresistance in NPC from 2012 until 2023. From our search, 15 studies were included....
Cyclin D1's role in radiotherapy resistance is elucidated through several mechanisms, notably SHP-1 and B-catenin. Overexpression of SHP-1 led to an increase in cyclin D1, a higher proportion of cells...
In conclusion, Cyclin D1 has a strong correlation with radiation resistance; downregulation of the protein increases radiosensitivity, while overexpression of the protein promotes radioresistance....
The aim was to gain insight into the biology of primary cutaneous CD4...
We describe the histopathological and clinical characteristics of 177 PCSM-LPD diagnosed at our consultation centre. We performed immunohistochemical multistaining in a subset of cases (n = 46) includ...
The cohort of n = 177 PCSM-LPD included 84 males and 93 females (median age 57, range 13-85). Clinical presentation was as a solitary nodule or plaque (head and neck > trunk > extremities). Most patie...
PCSM-LPD is a clinically indolent, albeit neoplastic, disease driven by clonal expansion of PD1(+)-cells. We demonstrate Cyclin D1-expression associated with accelerated proliferation as a surprising ...